SA News • Mon, Nov. 10
Be smarter and faster with PRO Alerts on MRTX
There is research on this stock available only to PRO subscribers.
Mirati Therapeutics: Investing In A Piece Of The Precision Medicine Pie
- "Precision Medicine" is a proven and continuously developing paradigm in cancer treatment.
- Mirati has two early targeted oncology candidates that build on the concept of precision medicine, both of which have scientific rationale for clinical success.
- Mirati's management has unique and significant expertise in bringing targeted oncology products to market, fast.
There are no Transcripts on MRTX.
Mon, Nov. 10, 8:27 AM
Fri, Aug. 8, 9:18 AM
Fri, Aug. 8, 8:08 AM
Tue, Jun. 17, 10:42 AM
- The FDA designates Mirati Therapeutics' (MRTX +0.1%) spectrum selective HDAC inhibitor mocetinostat an Orphan Drug for the treatment of myelodysplastic syndrome (MDS). Mirati is developing the product in combination with Vidaza as a treatment for intermediate and high-risk MDS and as a single agent treatment for diffuse large B-cell lymphoma and bladder cancer.
Thu, May. 15, 5:25 PM
Mon, Mar. 17, 4:57 PM
Dec. 18, 2013, 10:03 AM
- Susquehanna starts Acadia Healthcare (ACHC +1.3%) at Positive. Price target is $56.
- Jefferies starts Mirati Therapeutics (MRTX +1.9%) at Buy. Price target is $36.
- KeyBanc initiates DaVita (DVA +1.5%) at Buy. Price target is $73.
- JMP starts Illumina (ILMN +1.1%) at Market Outperform. Price target is $125.
- KeyBanc starts IPC (IPCM -0.6%) at Hold.
- KeyBanc starts Envision Healthcare (EVHC +1.6%) at Buy. Price target is $40.
- JMP starts Quest Diagnostics (DGX -0.9%) at Market Perform.
- KeyBanc starts Team Health (TMH -0.8%) at Hold.
- JMP starts Lab Corp (LH -0.3%) at Market Perform.
- Goldman upgrades HCA Holdings (HCA +1.6%) to Conviction Buy.
- MKM downgrades Targacept (TRGT -3.1%) to Neutral from Buy.
Nov. 12, 2013, 8:57 AM
Oct. 24, 2013, 9:18 PM| Comment!
Oct. 16, 2013, 4:26 PM
MRTX vs. ETF Alternatives
Other News & PR